FDA approval expected for expanded use of Zevalin

09/4/2009 | Reuters

Analysts are expecting the FDA to approve the use of Spectrum Pharmaceuticals' cancer drug Zevalin as a first-line treatment for non-Hodgkin's lymphoma. The drug currently is approved as treatment for relapsed or refractory NHL. The FDA is set to hand down its decision on Monday.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Director, Quality Regulatory Affairs
Cardinal Health
Chicago, IL
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC